Lifeward Secures $47M Oramed Funding, Acquires AI Exoskeleton Technology
Lifeward won shareholder approval to acquire Oramed’s POD™ platform, granting Oramed up to 49.99% equity and unlocking $47 million funding toward cash flow positivity. It also acquired a powered upper-body exoskeleton with AI and secured Medicare Advantage coverage from Aetna, Humana and UnitedHealthcare for its ReWalk device covering 16 million lives.
1. Oramed Strategic Collaboration
Lifeward received shareholder approval to acquire Oramed’s Protein Oral Delivery (POD™) platform, with Oramed obtaining up to 49.99% equity ownership. The deal provides up to $47 million in development funding and positions Lifeward to access an oral insulin pipeline while limiting its capital commitments.
2. Acquisition of Upper-Body Exoskeleton
The company entered into an agreement to acquire a powered upper-body exoskeleton with integrated AI capabilities. This technology complements the ReWalk platform by leveraging existing sales, distribution and reimbursement infrastructure, with a commercial launch anticipated in 18 to 24 months and attractive unit economics.
3. Expanded Reimbursement Coverage
Lifeward secured Medicare Advantage coverage for its ReWalk Personal Exoskeleton from Aetna, Humana and UnitedHealthcare, extending access to approximately 16 million covered lives in the U.S. This milestone enhances patient access and reinforces clinical validation of robotic rehabilitation solutions.
4. Operational and Commercial Updates
During 2025, Lifeward restructured its U.S. sales model into direct-to-patient engagement, institutional capital equipment sales and expanded payer partnerships. Improved operational discipline reduced GAAP operating expenses and cash usage, setting the stage for revenue growth and cash flow positivity in 2026.